Cuffaro F, Lamminpaa I, Niccolai E, Amedei A
Nutrients. 2025; 17(1.
PMID: 39796536
PMC: 11722677.
DOI: 10.3390/nu17010102.
Jacob S, Lee S, Kim S, Sharkey K, Pfeffer G, Nguyen M
Nat Rev Neurol. 2024; 20(8):475-494.
PMID: 38965379
DOI: 10.1038/s41582-024-00991-7.
Nogradi B, Nogradi-Halmi D, Erdelyi-Furka B, Kadar Z, Csont T, Gaspar R
Cell Death Discov. 2024; 10(1):291.
PMID: 38898006
PMC: 11187107.
DOI: 10.1038/s41420-024-02055-7.
Lee A, Henderson R, Aylward J, McCombe P
Int J Mol Sci. 2024; 25(3).
PMID: 38339149
PMC: 10856138.
DOI: 10.3390/ijms25031871.
Oprisan A, Popescu B
Int J Mol Sci. 2023; 24(19).
PMID: 37834374
PMC: 10573406.
DOI: 10.3390/ijms241914927.
Early activation of cellular stress and death pathways caused by cytoplasmic TDP-43 in the rNLS8 mouse model of ALS and FTD.
Luan W, Wright A, Brown-Wright H, Le S, San Gil R, Madrid San Martin L
Mol Psychiatry. 2023; 28(6):2445-2461.
PMID: 37012334
PMC: 10611572.
DOI: 10.1038/s41380-023-02036-9.
Ozone modified hypothalamic signaling enhancing thermogenesis in the TDP-43 transgenic model of Amyotrophic Lateral Sclerosis.
Rodriguez-Sanchez S, Valiente N, Sesena S, Cabrera-Pinto M, Rodriguez A, Aranda A
Sci Rep. 2022; 12(1):20814.
PMID: 36460700
PMC: 9718766.
DOI: 10.1038/s41598-022-25033-4.
A Gut Feeling in Amyotrophic Lateral Sclerosis: Microbiome of Mice and Men.
Martin S, Battistini C, Sun J
Front Cell Infect Microbiol. 2022; 12:839526.
PMID: 35360111
PMC: 8963415.
DOI: 10.3389/fcimb.2022.839526.
Modelling amyotrophic lateral sclerosis in rodents.
Todd T, Petrucelli L
Nat Rev Neurosci. 2022; 23(4):231-251.
PMID: 35260846
DOI: 10.1038/s41583-022-00564-x.
Low-level overexpression of wild type TDP-43 causes late-onset, progressive neurodegeneration and paralysis in mice.
Yang C, Qiao T, Yu J, Wang H, Guo Y, Salameh J
PLoS One. 2022; 17(2):e0255710.
PMID: 35113871
PMC: 8812852.
DOI: 10.1371/journal.pone.0255710.
The potential benefit of leptin therapy against amyotrophic lateral sclerosis (ALS).
Ferrer-Donato A, Contreras A, Fernandez P, Fernandez-Martos C
Brain Behav. 2021; 12(1):e2465.
PMID: 34935299
PMC: 8785645.
DOI: 10.1002/brb3.2465.
Alterations in Leptin Signaling in Amyotrophic Lateral Sclerosis (ALS).
Ferrer-Donato A, Contreras A, Frago L, Chowen J, Fernandez-Martos C
Int J Mol Sci. 2021; 22(19).
PMID: 34638645
PMC: 8508891.
DOI: 10.3390/ijms221910305.
Extensive phenotypic characterisation of a human TDP-43 transgenic mouse model of amyotrophic lateral sclerosis (ALS).
Watkins J, Alix J, Shaw P, Mead R
Sci Rep. 2021; 11(1):16659.
PMID: 34404845
PMC: 8370970.
DOI: 10.1038/s41598-021-96122-z.
Small junction, big problems: Neuromuscular junction pathology in mouse models of amyotrophic lateral sclerosis (ALS).
Alhindi A, Boehm I, Chaytow H
J Anat. 2021; 241(5):1089-1107.
PMID: 34101196
PMC: 9558162.
DOI: 10.1111/joa.13463.
Methodology Aspects of Colony Maintain for a Murine Model of Amyotrophic Lateral Sclerosis (ALS) TDP-43 Proteinopathy.
Alvaro-Alonso C, Ferrer-Donato A, Fernandez-Torres E, Carballo-Villa M, Fernandez-Martos C
Animals (Basel). 2020; 10(12).
PMID: 33297584
PMC: 7762410.
DOI: 10.3390/ani10122329.
Diet, Microbiota and Brain Health: Unraveling the Network Intersecting Metabolism and Neurodegeneration.
Gentile F, Doneddu P, Riva N, Nobile-Orazio E, Quattrini A
Int J Mol Sci. 2020; 21(20).
PMID: 33050475
PMC: 7590163.
DOI: 10.3390/ijms21207471.
Monoclonal full-length antibody against TAR DNA binding protein 43 reduces related proteinopathy in neurons.
Pozzi S, Codron P, Soucy G, Renaud L, Cordeau P, Dutta K
JCI Insight. 2020; 5(21).
PMID: 33021970
PMC: 7710295.
DOI: 10.1172/jci.insight.140420.
Non-invasive characterization of amyotrophic lateral sclerosis in a hTDP-43 mouse model: A PET-MR study.
Weerasekera A, Crabbe M, Tome S, Gsell W, Sima D, Casteels C
Neuroimage Clin. 2020; 27:102327.
PMID: 32653817
PMC: 7352080.
DOI: 10.1016/j.nicl.2020.102327.
C9orf72-specific phenomena associated with frontotemporal dementia and gastrointestinal symptoms in the absence of TDP-43 aggregation.
Sampognaro P, Vatsavayai S, Cosme C, Hwang J, Nolan A, Huang E
Acta Neuropathol. 2019; 138(6):1093-1097.
PMID: 31624869
PMC: 6858587.
DOI: 10.1007/s00401-019-02084-y.
Long-term interleukin-33 treatment delays disease onset and alleviates astrocytic activation in a transgenic mouse model of amyotrophic lateral sclerosis.
Korhonen P, Pollari E, Kanninen K, Savchenko E, Lehtonen S, Wojciechowski S
IBRO Rep. 2019; 6:74-86.
PMID: 30705990
PMC: 6348738.
DOI: 10.1016/j.ibror.2019.01.005.